Free Trial
→ Tesla pays zero dividends but this new fund pays monthly (From Investors Alley) (Ad)tc pixel
NASDAQ:IBRX

ImmunityBio Q3 2026 Earnings Results & Report

ImmunityBio logo
$7.12 -1.52 (-17.56%)
As of 12:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ImmunityBio missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.0920 versus the -$0.07 consensus estimate, while revenue of $48.84 million fell short of the $59.23 million estimate by $10.38 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
7:30 AM ET

ImmunityBio EPS Results

Actual EPS
-$0.0920
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.0220
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

ImmunityBio Revenue Results

Actual Revenue
$48.84 million
Expected Revenue
$59.23 million
Beat/Miss
Missed by -$10.38 million
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

ImmunityBio's Q3 2026 Press ReleasePress Release
(8-K)
ImmunityBio's Q3 2026 Quarterly reportQuarterly report
(10-Q)

ImmunityBio Q3 2026 Earnings FAQ

ImmunityBio (NASDAQ:IBRX) reported earnings of -$0.0920 per share for Q3 2026, missing the consensus estimate of -$0.07. The report was announced on Monday, November 9, 2026.

ImmunityBio reported revenue of $48.84 million for Q3 2026, against a consensus estimate of $59.23 million.

ImmunityBio Earnings Headlines

ImmunityBio Reports Wider Quarterly Loss
 |  benzinga.comhttps://www.benzinga.com/markets/earnings/26/11/63041433/immunitybio-reports-wider-quarterly-loss?utm_source=snapi
ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/immunitybio-ibrx-reports-q3-loss-125001114.html
My prediction for December 8th
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
November 9 at 1:00 AM  |  Behind the Markets (Ad)
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
 |  businesswire.comhttps://www.businesswire.com/news/home/20261109683136/en/ImmunityBio-Reports-Label-Expansion-and-Additional-Global-Approval-with-Q3-2026-Net-Product-Revenue-of-48.7-Million-Up-53-Year-Over-Year-and-First-Nine-Months-U.S.-Revenue-Up-92-to-143.6-Million/
ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
November 9 at 7:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261109448906/en/ImmunityBio-Announces-ANKTIVA%C2%AE-Plus-BCG-Meets-Primary-Endpoint-in-BCG-Na%C3%AFve-Non-Muscle-Invasive-Bladder-Cancer-Randomized-QUILT-2.005-Trial/
ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
November 5, 2026  |  marketscreener.comM
See More ImmunityBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email.

About ImmunityBio

ImmunityBio (NASDAQ:IBRX) is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses.

The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio also has investigational treatments in development for cancer and other diseases.

ImmunityBio was formed through the combination of ImmunityBio and NantKwest, completed in 2021. The company is based in California and conducts research and development and commercial activities focused on bringing its therapies to patients.

View ImmunityBio Profile
Earnings Tools